<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943707</url>
  </required_header>
  <id_info>
    <org_study_id>12330000470005914R</org_study_id>
    <nct_id>NCT02943707</nct_id>
  </id_info>
  <brief_title>Autologous Bone Marrow Stem Cells Infusion for the Treatment of Liver Diseases.</brief_title>
  <acronym>ABMSCIFTLD</acronym>
  <official_title>Autologous Bone Marrow Stem Cells Infusion for the Treatment of Liver Diseases.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wenzhou Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of autologous bone marrow stem cells infusion (ABMSCi)
      therapy for liver diseases.Treatment group will receive ABMSCi and drugs therapy ,while
      control group will only receive drugs therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Autologous bone marrow stem cells (ABMSC) mobilization and harvest For harvesting more
           ABMSC, ABMSC mobilization is induced by recombinant human granulocyte colony stimulating
           factor (rhGCSF,Gran○R), administered subcutaneously at a dose of 300μg daily for three
           consecutive days before bone marrow puncture.

           Bone marrow (160-200ml) of the patients is harvested from both posterior superior iliacs
           according to standard procedures under local anaesthesia and is collected in a plastic
           bag containing heparin.

        2. Both treatment group and control group receive drugs therapy.

        3. ABMSC separation and infusion ABMSC is separated and purified in a class 10,000 clean
           laboratory. After fat and bony particles are removed by filtration, collected cells are
           moved to a cell-processing device. The reagents adopt the method of negative cells
           collection. Take the cells which intended to remove as target cells, and carry out the
           removal step-by-step. On the basis of this method, red blood cells, blood platelets,
           blood plasma will be completely removed with part of white cells and lymphocytes being
           remarkably removed as well while all the stem cells / progenitor cells are being well
           retained.

           The nucleated cell (white blood cell) count of final ABMSC is measured by an automated
           complete blood count instrument and flow cytometry analysis. The number of mononuclear
           cells is counted manually under a microscope by Wright-Giemsa stain method. Cell
           differentiation factor 34(CD34) positive cells were determined by flow cytometry
           analysis.

           The time of ABMSC separation and purification is 2.5-3 hours. ABMSC is added to 10 ml
           saline and well mixed by shaking the vial gently. The catheter is pushed to reach the
           proper hepatic artery. The diameter of the catheter is 1.4mm, it is thin enough to
           easily been inserted to right gastric artery . The mixture of saline and ABMSC is
           infused into proper hepatic artery at uniform speed for about two minutes. The catheter
           is removed after the ABMSCi.

        4. Statistical analysis - Categorical data are presented as absolute values and
           percentages, whereas continuous data are summarized as mean and Standard Deviation.
           Statistical analysis was performed using t-test for paired or unpaired samples. Time
           courses of measurements of liver function parameters were analyzed by repeated-measures
           ANOVA. The analysis is performed using the Statistic Package for Social Science (SPSS).
           All statistical analysis is based on two-tailed hypothesis tests with a significance
           level of p&lt; 0.05.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline alanine aminotransferase at 6 months</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>alanine aminotransferase (ALT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline aspartate aminotransferase at 6 months</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>aspartate aminotransferase (AST)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline total bilirubin at 6 months</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>total bilirubin (TBil)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline direct bilirubin at 6 months</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>direct bilirubin (DBil)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline total bile acid at 6 months</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>total bile acid (TBA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline albumin at 6 months</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>albumin (ALB)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline prothrombin time at 6 months</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>prothrombin time (PT),</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline international normalized ratio at 6 months</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>international normalized ratio (INR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline white blood cell at 6 months</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>white blood cell (WBC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline platelet at 6 months</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>platelet (PLT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline liver density at 6 months</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>Low density, medium density, high density tested by abdominal B ultrasound/CT/MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline liver size at 6 months</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>Enlarged size, normal size, shrunken size tested by abdominal B ultrasound/CT/MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline spleen thickness at 6 months</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>tested by abdominal B ultrasound/CT/MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events that are related to treatment</measure>
    <time_frame>baseline and 6 months after treatment</time_frame>
    <description>Postoperative pyrexia, infection, liver cirrhosis, ascites, upper gastrointestinal hemorrhage, malignant tumors of liver and other organs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that survive without developing disease</measure>
    <time_frame>12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that survive with developing disease</measure>
    <time_frame>12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that die after treatment</measure>
    <time_frame>12 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>treatment group: ABMSCi &amp; drugs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABMSCi: Autologous bone marrow stem cells infusion drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group: drugs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>drugs such as Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous bone marrow stem cells infusion</intervention_name>
    <description>Autologous bone marrow stem cells are infused into proper hepatic artery</description>
    <arm_group_label>treatment group: ABMSCi &amp; drugs</arm_group_label>
    <other_name>ABMSCi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>drugs such as Ursodeoxycholic Acid tablets</intervention_name>
    <description>Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally</description>
    <arm_group_label>treatment group: ABMSCi &amp; drugs</arm_group_label>
    <arm_group_label>control group: drugs</arm_group_label>
    <other_name>UDCA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Definite liver diseases (such as viral hepatitis, autoimmune liver diseases, fatty
             liver diseases, ect);

          2. Active bone marrow hyperplasia showed by bone marrow biopsy before ABMSCi;

          3. Age between 18 and 60 years;

          4. Abnormal liver function.

        Exclusion Criteria:

          1. Enlisted for liver transplantation

          2. Diagnosis of hepatocellular carcinoma or other cancers

          3. Other severe medical disease, and acute infection

          4. pregnant or nursing females,co-infections with HIV ,serious bacterial infection

          5. other vital organ or system dysfunction

          6. with severe complications of liver cirrhosis

          7. hematological disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yongping chen</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Wenzhou Medical Univeristy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yongping chen</last_name>
    <phone>8613505777281</phone>
    <email>13505777281@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>lanman xu</last_name>
    <phone>8613587646315</phone>
    <email>13587646315@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yongping chen</last_name>
      <phone>8613505777281</phone>
      <email>13505777281@163.com</email>
    </contact>
    <contact_backup>
      <last_name>lanman xu</last_name>
      <phone>8613587646315</phone>
      <email>13587646315@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>yongping chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>lanman xu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>dazhi chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>minghua zheng, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>keqing shi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>yu huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>faling wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>ruicong chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>yunlei xiao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ma XR, Tang YL, Xuan M, Chang Z, Wang XY, Liang XH. Transplantation of autologous mesenchymal stem cells for end-stage liver cirrhosis: a meta-analysis based on seven controlled trials. Gastroenterol Res Pract. 2015;2015:908275. doi: 10.1155/2015/908275. Epub 2015 Mar 15. Review.</citation>
    <PMID>25861263</PMID>
  </reference>
  <results_reference>
    <citation>Xu L, Gong Y, Wang B, Shi K, Hou Y, Wang L, Lin Z, Han Y, Lu L, Chen D, Lin X, Zeng Q, Feng W, Chen Y. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells. J Gastroenterol Hepatol. 2014 Aug;29(8):1620-8. doi: 10.1111/jgh.12653.</citation>
    <PMID>24942592</PMID>
  </results_reference>
  <results_reference>
    <citation>Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, Zheng YB, Gao ZL. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011 Sep 2;54(3):820-8. doi: 10.1002/hep.24434. Epub 2011 Jul 14.</citation>
    <PMID>21608000</PMID>
  </results_reference>
  <results_reference>
    <citation>Deng Q, Cai T, Zhang S, Hu A, Zhang X, Wang Y, Huang J. Autologous Peripheral Blood Stem Cell Transplantation Improves Portal Hemodynamics in Patients with Hepatitis B Virus-related Decompensated Cirrhosis. Hepat Mon. 2015 Dec 20;15(12):e32498. doi: 10.5812/hepatmon.32498. eCollection 2015 Dec.</citation>
    <PMID>26977164</PMID>
  </results_reference>
  <results_reference>
    <citation>Mohamadnejad M, Vosough M, Moossavi S, Nikfam S, Mardpour S, Akhlaghpoor S, Ashrafi M, Azimian V, Jarughi N, Hosseini SE, Moeininia F, Bagheri M, Sharafkhah M, Aghdami N, Malekzadeh R, Baharvand H. Intraportal Infusion of Bone Marrow Mononuclear or CD133+ Cells in Patients With Decompensated Cirrhosis: A Double-Blind Randomized Controlled Trial. Stem Cells Transl Med. 2016 Jan;5(1):87-94. doi: 10.5966/sctm.2015-0004. Epub 2015 Dec 10.</citation>
    <PMID>26659833</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen Y, Chen S, Liu LY, Zou ZL, Cai YJ, Wang JG, Chen B, Xu LM, Lin Z, Wang XD, Chen YP. Mesenchymal stem cells ameliorate experimental autoimmune hepatitis by activation of the programmed death 1 pathway. Immunol Lett. 2014 Dec;162(2 Pt B):222-8. doi: 10.1016/j.imlet.2014.10.021. Epub 2014 Oct 28.</citation>
    <PMID>25445618</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wenzhou Medical University</investigator_affiliation>
    <investigator_full_name>yongping chen</investigator_full_name>
    <investigator_title>Director,Clinical Research</investigator_title>
  </responsible_party>
  <keyword>liver diseases</keyword>
  <keyword>Bone Marrow Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

